心房颤动用新型抗凝药物的研究进展

Advances in the study of new anticoagulant drugs for atrial fibrillation

心房颤动是目前临床上最常见的心律失常类型之一,是缺血性卒中的重要的独立危险因素。抗凝治疗是降低心房颤动相关卒中死亡率的关键。华法林是现心房颤动患者使用最广泛的抗凝药物,但由于其药代动力学特点和临床用药的复杂性,严重影响了华法林的使用率和患者的依从性。本文介绍心房颤动用新型抗凝药物的研究进展。

Atrial fibrillation is still one of the most common clinical arrhythmias, of which ischemic stroke is an important independent risk factor. Anticoagulant therapy is the key to decrease mortality of stroke related to atrial fibrillation. Warfarin is the most widely used anticoagulant drug in patients with atrial fibrillation currently, however, the use of warfarin and the patient compliance with it are seriously affected because of its pharmacokinetic characteristics and complexity of clinical application. This article reviews the research progress in the anticoagulant therapies for atrial fibrillation.